Roche Holding Gestione

Gestione criteri di controllo 2/4

Roche Holding Il CEO è Thomas Schinecker, nominato in Mar2023, ha un mandato di 1.67 anni. possiede direttamente 0% delle azioni della società, per un valore di $ 1.04M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 7.7 anni.

Informazioni chiave

Thomas Schinecker

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.7yrs
Proprietà del CEO	0.0004%
Durata media del management	4.8yrs
Durata media del Consiglio di amministrazione	7.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Thomas Schinecker rispetto agli utili di Roche Holding?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	CHF 11b
Mar 31 2024	n/a	n/a	CHF 11b
Dec 31 2023	n/a	n/a	CHF 11b
Sep 30 2023	n/a	n/a	CHF 11b
Jun 30 2023	n/a	n/a	CHF 11b
Mar 31 2023	n/a	n/a	CHF 12b
Dec 31 2022	CHF 5m	CHF 1m	CHF 12b
Sep 30 2022	n/a	n/a	CHF 14b
Jun 30 2022	n/a	n/a	CHF 15b
Mar 31 2022	n/a	n/a	CHF 14b
Dec 31 2021	CHF 4m	CHF 1m	CHF 14b
Sep 30 2021	n/a	n/a	CHF 14b
Jun 30 2021	n/a	n/a	CHF 14b
Mar 31 2021	n/a	n/a	CHF 14b
Dec 31 2020	CHF 4m	CHF 879k	CHF 14b
Sep 30 2020	n/a	n/a	CHF 14b
Jun 30 2020	n/a	n/a	CHF 13b
Mar 31 2020	n/a	n/a	CHF 13b
Dec 31 2019	CHF 2m	CHF 609k	CHF 13b

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Thomas sia ragionevole rispetto ad aziende di dimensioni simili nel mercato UK.

Compensazione vs guadagni: La retribuzione di Thomas è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Thomas Schinecker (49 yo)

1.7yrs

Mandato

CHF 5,335,592

Compensazione

Dr. Thomas Schinecker serves as Chairman of the Board at Genentech, Inc. since March 2023. He serves as Chief Executive Officer at Roche Holding AG since March 15, 2023. He has been Chief Executive Officer...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Severin Schwan	Executive Chairman	11.7yrs	CHF 11.48m	0.043% $ 99.0m
Thomas Schinecker	Chief Executive Officer	1.7yrs	CHF 5.34m	0.00045% $ 1.0m
Alan Hippe	Chief Financial & Information Officer	13.6yrs	CHF 6.05m	0.0063% $ 14.5m
Bruno Eschli	Head of Investor Relations	no data	Nessun dato	Nessun dato
Claudia Bockstiegel	General Counsel	4.6yrs	Nessun dato	Nessun dato
Pascale Schmidt	Chief Compliance Officer	4.8yrs	Nessun dato	Nessun dato
Barbara Schadler	Head of Group Communications	5.1yrs	Nessun dato	Nessun dato
Cristina Wilbur	Chief People Officer	8.7yrs	CHF 4.25m	0.0020% $ 4.6m
Nicolas Dunant	Head of Group Media Relations	no data	Nessun dato	Nessun dato
Boris Zaitra	Head of Corporate Business Development	no data	Nessun dato	Nessun dato
Paulo Fontoura	Head of Neuroscience Clinical Development	no data	Nessun dato	Nessun dato
Johannes Clevers	Head of Roche Pharma Research & Early Development	2.7yrs	CHF 82.50k	Nessun dato

4.8yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di 0TDF è considerato esperto (durata media dell'incarico 4.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Severin Schwan	Executive Chairman	11.7yrs	CHF 11.48m	0.043% $ 99.0m
Bernard Poussot	Non-Executive Independent Director	9.8yrs	CHF 330.00k	0.00013% $ 299.4k
Ulf Schneider	Director	1.7yrs	Nessun dato	0.00063% $ 1.5m
Andre Hoffmann	Independent Vice Chairman	28.8yrs	CHF 402.82k	3.53% $ 8.1b
Patrick Frost	Independent Non Executive Director	4.7yrs	CHF 360.00k	0.00025% $ 575.7k
Richard Lifton	Non-Executive Independent Director	9.8yrs	CHF 346.71k	0% $ 0
Anita Hauser	Non-Executive Independent Director	7.7yrs	CHF 336.16k	0.00040% $ 921.2k
Jorg Duschmale	Non-Executive Independent Director	4.7yrs	CHF 364.59k	Nessun dato
Akiko Iwasaki	Director	1.7yrs	Nessun dato	Nessun dato
Claudia Ricarda Suessmuth Dyckerhoff	Non-Executive Independent Director	8.7yrs	CHF 367.02k	0.00034% $ 783.0k
Jemilah Mahmood	Independent Non-Executive Director	2.7yrs	CHF 272.50k	Nessun dato

7.7yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0TDF sono considerati esperti (durata media dell'incarico 7.7 anni).

Roche Holding Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Roche Announces Management and Board Committee Changes

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Recent updates

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media